In recent years, an increasing percentage of my time is devoted to societal decision making. This work focuses on how pharmaceutical firms “pay-for-delay” of generic entry, and cost consumers billions of unnecessary dollars in the process.  This work also focuses on how to reform the insurance industry, and includes a recent paper in HBS with Danny Kahneman.